RWC Update: GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Concern or Coincidence?; The Glowport; Retinocytoma

The potential link between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION) has generated increasing debate, with limited and conflicting evidence to date.As use of these agents continues to expand, understanding of any true ocular risk is essential.In this column, expert perspectives help clarify the data, explore biological plausibility, and separate concern from coincidence.Cindy X. Cai, MD, MS.Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity because they effectively lower glucose and promote weight loss.Beyond these